An overview of oral contraceptives - Mechanism of action and clinical use

被引:64
作者
Frye, CA
机构
[1] SUNY Albany, Dept Psychol, Albany, NY 12203 USA
[2] SUNY Albany, Neurosci Res Ctr, Albany, NY 12203 USA
关键词
D O I
10.1212/WNL.66.66_suppl_3.S29
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hormonal contraception is available in oral contraceptive pills and in newer formulations, including the transdermal patch, the vaginal ring, subcutaneous implants, and IM injections. Prevention of pregnancy is achieved by inhibiting ovulation, fertilization, and/or implantation of an egg. Hormonal contraception provides effective, tolerable, and reversible prevention of pregnancy. Efficacy and safety profiles are similar for different formulations and administration routes. Lowest expected failure (i.e., method failure) rates for hormonal contraceptives, regardless of formulation, are < 2%. Typical failure rates for oral formulations range from < 3% to 5% due to failures in compliance. The most commonly reported adverse effects are weight gain, nausea, variations in menstrual flow, breast changes such as tenderness, discomfort, or swelling, depression or mood disturbances, decreased sexual desire or response, and acne. Rare but serious potential effects include cardiovascular diseases, such as stroke, and an increased risk for breast cancer, liver tumors, and gallbladder disease. Hormonal contraceptive use should be avoided in women at risk for blood clots, by heavy smokers, and in women with breast or other cancers. Use of hormonal contraception in adolescents requires special consideration, in part because of decreased compliance.
引用
收藏
页码:S29 / S36
页数:8
相关论文
共 71 条
[1]   THE USE OF NORPLANT AND DEPO-PROVERA IN ADOLESCENTS [J].
AMMERMAN, SD .
JOURNAL OF ADOLESCENT HEALTH, 1995, 16 (05) :343-346
[2]   A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[3]  
*BARR LAB INC, 2004, PREV EM CONTR PILLS
[4]  
BELL S, 1998, OUR BODIES OURSELVES, P288
[5]  
BERENSON AB, 1993, PEDIATRICS, V92, P257
[6]  
*BOST WOM HLTH BOO, 2005, OUR BOD OURS, P322
[7]  
CANNOLD L, 1996, HEALTHSHARING WO DEC, P14
[9]  
CORONA CA, 2000, NECON PACKAGE INSERT
[10]  
CORONA CA, 2004, MICROGESTIN PACKAGE